Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Frailty and Ultrasound-Guided Central Venous Catheterization Difficulty in Adult Cardiac Surgery Patients

NCT07701538 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-07-25
Last updated
2026-07-14

Condition(s) studied

FrailtyCardiac SurgeryCentral Venous Catheter

Investigational drug(s) / intervention(s)

Ultrasound-Guided Internal Jugular Vein Catheterization

Ultrasound-Guided Internal Jugular Vein Catheterization: Ultrasound-guided internal jugular vein catheterization performed as part of routine perioperative clinical care in adult cardiac surgery patients. No additional study-specific intervention is performed.

Study summary

This prospective observational study aims to evaluate the association between preoperative frailty and the procedural difficulty of ultrasound-guided internal jugular vein catheterization in adult patients undergoing elective cardiac surgery.

Frailty will be assessed using the Clinical Frailty Scale and handgrip strength measurements. Preprocedural ultrasound evaluation will include internal jugular vein anatomical characteristics such as anteroposterior and transverse vein diameters, cross-sectional area (CSA), common carotid artery diameter, skin-to-vein distance, overlap status, and sternocleidomastoid muscle thickness Catheterization difficulty will be assessed using the Gaber Procedural Difficulty Index.

The study seeks to determine whether frailty and ultrasound-derived anatomical parameters can predict difficult internal jugular venous catheterization and improve preprocedural risk assessment without altering routine clinical care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * Adults aged 18 years or older. * Scheduled for elective cardiac surgery. * Planned ultrasound-guided internal jugular vein catheterization as part of routine perioperative care. * Able to undergo preoperative frailty assessment using the Clinical Frailty Scale (CFS). * Able to perform handgrip strength measurement. * Able to undergo ultrasound assessment of the internal jugular vein. * Provided written informed consent. Exclusion Criteria Conditions Affecting Neck Anatomy 1. Previous neck surgery. 2. History of radiotherapy to the neck region. 3. Presence of a neck mass, infection, or any lesion that may distort neck anatomy. 4. Known internal jugular vein thrombosis. 5. Congenital vascular anomalies causing significant alteration of the internal jugular vein or carotid artery anatomy. Clinical Conditions Affecting Catheterization 1. Patients requiring emergency cardiac surgery. 2. Presence of an existing central venous catheter. 3. Severe coagulopathy (INR \> 2.0 or platelet count \< 50,000/mm³). 4. Hemodynamic instability or requirement for active cardiopulmonary resuscitation. Conditions Affecting Frailty and Handgrip Strength Assessment 1. Severe neurological disorders (e.g., advanced dementia or disabling sequelae of stroke). 2. Orthopedic or neuromuscular disorders affecting upper extremity function. 3. Inability to perform handgrip strength measurement due to severe arthritis or hand deformity. Conditions Affecting Study Participation 1. Cognitive impairment preventing reliable clinical assessment or informed participation. 2. Refusal to participate in the study. 3. Any other condition that, in the investigator's judgment, may compromise patient safety or interfere with study participation.

Primary outcome measure(s)

  • Difficult ultrasound-guided internal jugular vein catheterization — At completion of the catheterization procedure
    Difficult catheterization will be defined as a Gaber Procedural Difficulty Score \>4. The Gaber Procedural Difficulty Score will be calculated at the completion of the ultrasound-guided internal jugular vein catheterization procedure. The score includes four procedural domains: number of puncture attempts, cannulation time, procedure-related complications, and procedural success. Total scores range from 4 to 11 points, with higher scores indicating greater procedural difficulty.

Trial sites (1)

FacilityCityRegionStatus
Ankara Bilkent City Hospital Ankara Ankara
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07701538 on ClinicalTrials.gov ↗ ← All trials in Turkey